| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
59,530,000 |
| Market
Cap: |
22.03(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.26 - $1.09 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Clene is a clinical-stage pharmaceutical company focusing on the discovery, development, and commercialization of clean-surfaced nanotechnology therapeutics. Co. is focused on addressing the unmet medical needs in two areas: first, those related to central nervous system disorders including Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson's Disease; and second, those related to COVID-19, an infectious viral respiratory disease with serious and sometimes fatal co-morbidities. In addition to the development of clean-surfaced nanocrystals, Co.'s electro-crystal-chemistry platform can produce ionic solutions of various transition elements including silver, zinc, and others.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
8,091,457 |
14,277,489 |
| Total Buy Value |
$0 |
$0 |
$6,375,915 |
$13,286,946 |
| Total People Bought |
0 |
0 |
4 |
6 |
| Total Buy Transactions |
0 |
0 |
4 |
18 |
| Total Shares Sold |
58,500 |
58,500 |
58,500 |
102,230 |
| Total Sell Value |
$22,517 |
$22,517 |
$22,517 |
$183,367 |
| Total People Sold |
1 |
1 |
1 |
3 |
| Total Sell Transactions |
4 |
4 |
4 |
6 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Glanzman Robert |
Chief Medical Officer |
• – – |
2022-05-16 |
4 |
AS |
$2.03 |
$9,576 |
D/D |
(4,717) |
10,564 |
|
39% |
|
| General Resonance Llc |
10% Owner |
– – • |
2022-05-16 |
4 |
S |
$2.20 |
$400,000 |
D/D |
(181,818) |
15,560,212 |
|
-39% |
|
| Gay Jonathon |
|
– • – |
2022-05-16 |
4 |
B |
$2.08 |
$20,800 |
D/D |
10,000 |
68,745 |
0.01 |
39% |
|
| Wilcox Reed N |
|
– • – |
2022-05-02 |
4 |
OE |
$0.15 |
$15,000 |
D/D |
100,000 |
400,233 |
|
- |
|
| General Resonance Llc |
10% Owner |
– – • |
2022-04-21 |
4 |
S |
$3.01 |
$400,002 |
D/D |
(132,891) |
15,742,030 |
|
1% |
|
| Matlin David J |
|
– • – |
2022-04-20 |
4 |
B |
$3.01 |
$400,002 |
D/D |
132,891 |
1,844,288 |
0.01 |
-1% |
|
31 Records found
|
|
Page 2 of 2 |
|
|
0.02 (4.05%) 
